Key Focus:
CANCER
RESEARCH
Reimagining Cancer Discovery Through Genomics
Cancer research is entering a new era defined by molecular precision, not morphology. Genomics has become the cornerstone of modern oncology, enabling researchers to decode the complex landscape of mutations, expression patterns, and epigenetic changes that drive tumor initiation, progression, and resistance.
​
At AUGenomics, we help oncology researchers uncover these molecular signatures with next-generation sequencing (NGS), liquid biopsy profiling, and multi-omic integration. Whether your focus is tumor evolution, immune response, or therapeutic resistance, our sequencing solutions empower you to explore cancer biology at single-base resolution.
​
Cancer is not a single disease but a dynamic ecosystem of genomic alterations. Through advanced sequencing and bioinformatics, scientists can now identify driver mutations, characterize tumor heterogeneity, and trace clonal evolution across time and treatment. From discovery research to translational studies, genomics reveals the underlying mechanisms that make personalized cancer therapy possible.
01
Comprehensive mutation profiling (SNVs, indels, CNVs, fusions)
02
Identification of novel oncogenic drivers in tumor subtypes
03
Transcriptomic analysis to map tumor microenvironment or immune response
04
Methylation and epigenetic signature discovery for classification and risk stratification
05
Longitudinal tracking of clonal evolution and resistance via liquid biopsy
06
Development and validation of companion diagnostics
07
Multi-omic integration for predictive modeling of therapy response
Why Genomics is Transforming Cancer Research
Every tumor carries a unique genetic signature. Genomic sequencing provides a comprehensive view of these changes, from point mutations and copy number variations to fusion transcripts and methylation patterns. This molecular data informs:
-
Tumor classification and molecular subtyping
-
Biomarker identification for prognosis and therapy selection
-
Drug target discovery and resistance mechanism mapping
-
Real-time monitoring of tumor burden via circulating DNA (liquid biopsy)
At AUGenomics, we combine high-resolution sequencing with AI-assisted variant interpretation and multi-omic integration to deliver insights that accelerate discovery. Our methods capture both known oncogenic drivers and novel alterations—helping you uncover mechanisms that traditional panels might overlook.
Machine learning and advanced bioinformatics amplify the power of genomics by revealing hidden associations between mutations, immune signaling, and therapeutic response—fueling more predictive, data-driven oncology research.
Common Sample Types
We support a wide range of tumor and biofluid samples used in cancer research, including:
-
FFPE tumor tissue — archived clinical samples for retrospective studies
-
Fresh-frozen tumor tissue — optimal for high-quality RNA and DNA sequencing
-
cfDNA / ctDNA (plasma, serum) — liquid biopsy for non-invasive tumor profiling
-
Whole blood / PBMCs — immune monitoring and host response studies
-
Organoids / patient-derived xenografts (PDX) — preclinical model characterization
-
Bone marrow aspirates — hematologic malignancy profiling
-
Cerebrospinal fluid (CSF) — central nervous system tumor detection
-
Ascites or pleural fluid — metastatic tumor sampling
Tailored Solutions
AUGenomics supports cancer research at every stage—from discovery to validation.
-
Oncology Biomarker Discovery: Identify prognostic and predictive biomarkers across tumor cohorts.
-
Precision Oncology: Characterize patient-specific mutations for targeted therapy development.
-
Immuno-Oncology: Sequence immune repertoires and identify neoantigens or TCR signatures.
-
Liquid Biopsy: Detect and monitor circulating tumor DNA (ctDNA) for early detection and MRD tracking.
-
Cancer Epigenomics: Profile methylation and chromatin accessibility to uncover regulatory mechanisms.
-
Drug Discovery & Development: Evaluate off-target effects, pharmacogenomic markers, and treatment efficacy.
Explore our specialized sequencing solutions for cancer research:
Whole Genome Sequencing (WGS) · Whole Exome Sequencing (WES) · RNA Sequencing · cfDNA Sequencing · Single-Cell RNA-seq · Methylation Profiling
Why Us?
At AUGenomics, we don’t just process samples, we partner in discovery. Our team of genomic scientists, method developers, and bioinformaticians provide hands-on collaboration and tailored experimental design to help you generate publishable, actionable data.
We deliver:
-
Customized workflows for challenging tumor samples and low-input cfDNA
-
Ultra-fast turnaround (as little as 3–5 days for select services)
-
Transparent project tracking via our online portal
-
Superior data quality validated against industry standards
-
Cross-disciplinary expertise spanning oncology, immunology, and molecular diagnostics
-
Collaborative support from scientists who understand translational cancer research
Our mission is simple: to make complex genomics accessible, reliable, and radically fast—so you can focus on advancing cures.
Let’s Work Together
Get in touch so we can start working together.
